PUBLIC COMPANY
save$GLUEMonte Rosa Therapeutics, Inc.
$GLUE9.1600+0.99%Boston, MA, USupdated 7h ago
community read0 votes
pipeline
2
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
1Phase 11Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
- phase2Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
- phase2Study of Oral MRT-2359 in Selected Cancer Patients
- phase1A First-in-human, 3-part Study of MRT-8102 in Healthy Participants and Participants at Cardiovascular Risk With Elevated CRP
- phase1First-in-human Study of MRT-6160 in Healthy Subjects
🐶 Hiring Signal
News
- Novo’s troubled cardio drug could find niche in less sick patientsAt the American Heart Association conference, investigators were supportive of further studying Novo’s IL-6 inhibitor ziltivekimab in patients with less severe cardiovascular and kidney disease.biospace · 9d ago
- Evommune inks molecular glue deal worth $1.1B biobucks to fill pipeline gapEvommune is commiting $30 million upfront for Hinova Pharmaceuticals’ oral molecular glue degrader—a low-cost bet with a high probability of success, according to analysts, after clinical failures…biospace · 13d ago
- Evommune signs $1B deal with China’s Hinova to enter same molecular glue niche as NovartisEvommune has paid $30 million to China’s Hinova Pharmaceuticals to get stuck into a niche of preclinical molecular glue degrader development that’s also being pursued by Novartis.fiercebiotech · 13d ago
- This week in charts: Moderna’s massive stock runThe latest installment in BioPharma Dive’s data visualization-focused series includes a look at Moderna’s meteoric rise in 2026 and a sudden deal surge from Roche.biopharma_dive · 1mo ago
- STAT+: FDA adcomm members’ ties to industry under scrutinyNew research found that nearly 40% of FDA advisory meetings held over a recent 20-year period included either a patient or consumer rep with active ties to an advocacy group…stat · 1mo ago
- STAT+: Concerns grow on safety issues tied to Neurocrine Biosciences rare disease drugPatient advocates and some experts are expressing growing alarm over the perceived risks of a rare disease drug sold by Neurocrine Biosciences.stat · 1mo ago
- The 2026 Biotech GraveyardFierce’s biotech graveyard is an annual tradition in which we remember all the companies we lost over the past year. While we're embracing the spooky spirit of Halloween, we hope the sad stories of…fiercebiotech · 1mo ago
- STAT+: Life Biosciences share glaucoma study updates for its cellular reprogramming drugLife Biosciences said yesterday that three glaucoma patients have now received a single injection of its experimental cellular reprogramming drug, with no serious adverse events.stat · 1mo ago
- STAT+: Roche goes beyond licensing in deal with Chinese biotechRoche is partnering with Chinese startup Defand Therapeutics to discover new medicines.stat · 1mo ago
- STAT+: Argenx sees unusual setback with failure of late-stage study of drug for autoimmune diseaseArgenx said its blockbuster drug Vyvgart didn’t outperform placebo in a Phase 3 trial of patients with Sjögren's disease, a chronic autoimmune disorder.stat · 1mo ago
Data sources
last refreshed 26m ago
Found something off?
comments(0)
5-min edit window · permanent after that